The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 11, 2022 | Altarac David | Chief Medical Officer | Disposed to issuer(D) | 150K | — | — |
| Jul 11, 2022 | Altarac David | Chief Medical Officer | Other(J) | 50K | — | $0 |
| Jul 11, 2022 | Altarac David | Chief Medical Officer | Other(J) | 92K | — | $0 |
| Jul 11, 2022 | Berger Heather A. | Director | Disposed to issuer(D) | 28K | $2.20 | $61K |
| Jul 11, 2022 | Berger Heather A. | Director | Other(J) | 17K | — | $0 |
| Jul 11, 2022 | Berger Heather A. | Director | Other(J) | 11K | — | $0 |
| Jul 11, 2022 | Hastings David C | Director | Disposed to issuer(D) | 28K | $2.20 | $61K |
| Jul 11, 2022 | Hastings David C | Director | Other(J) | 27K | — | $0 |
| Jul 11, 2022 | Hastings David C | Director | Other(J) | 11K | — | $0 |
| Jul 11, 2022 | Keiley Elizabeth M | General Counsel | Disposed to issuer(D) | 150K | — | — |
| Jul 11, 2022 | Keiley Elizabeth M | General Counsel | Other(J) | 50K | — | $0 |
| Jul 11, 2022 | Keiley Elizabeth M | General Counsel | Other(J) | 21K | — | $0 |
| Jul 11, 2022 | Mayer Howard | Director | Disposed to issuer(D) | 28K | $2.20 | $61K |
| Jul 11, 2022 | Mayer Howard | Director | Other(J) | 13K | — | $0 |
| Jul 11, 2022 | Mayer Howard | Director | Other(J) | 11K | — | $0 |
| Jul 11, 2022 | Meek David D. | Director | Disposed to issuer(D) | 28K | $2.20 | $61K |
| Jul 11, 2022 | Meek David D. | Director | Other(J) | 17K | — | $0 |
| Jul 11, 2022 | Meek David D. | Director | Other(J) | 11K | — | $0 |
| Jul 11, 2022 | Mueller John Patrick | Chief Development Officer | Disposed to issuer(D) | 150K | — | — |
| Jul 11, 2022 | Mueller John Patrick | Chief Development Officer | Other(J) | 76K | — | $0 |
| Jul 11, 2022 | Mueller John Patrick | Chief Development Officer | Other(J) | 50K | — | $0 |
| Jul 11, 2022 | Mueller John Patrick | Chief Development Officer | Other(J) | 25K | — | $0 |
| Jul 11, 2022 | Mueller John Patrick | Chief Development Officer | Other(J) | 18K | — | $0 |
| Jul 11, 2022 | Perros Manoussos | President and CEO, Director | Disposed to issuer(D) | 479K | — | — |
| Jul 11, 2022 | Perros Manoussos | President and CEO, Director | Other(J) | 145K | — | $0 |
| Jul 11, 2022 | Perros Manoussos | President and CEO, Director | Other(J) | 326K | — | $0 |
| Jul 11, 2022 | Perros Manoussos | President and CEO, Director | Other(J) | 70K | — | $0 |
| Jul 11, 2022 | Perros Manoussos | President and CEO, Director | Other(J) | 183K | — | $0 |
| Jul 11, 2022 | Ronsheim Matthew | Chief of Pharma Sciences & MFG | Disposed to issuer(D) | 150K | — | — |
| Jul 11, 2022 | Ronsheim Matthew | Chief of Pharma Sciences & MFG | Other(J) | 20K | — | $0 |
| Jul 11, 2022 | Ronsheim Matthew | Chief of Pharma Sciences & MFG | Other(J) | 15K | — | $0 |
| Jul 11, 2022 | Ronsheim Matthew | Chief of Pharma Sciences & MFG | Other(J) | 33K | — | $0 |
| Jul 11, 2022 | Ronsheim Matthew | Chief of Pharma Sciences & MFG | Other(J) | 20K | — | $0 |
| Jul 11, 2022 | Tommasi Ruben | Chief Scientific Officer | Disposed to issuer(D) | 150K | — | — |
| Jul 11, 2022 | Tommasi Ruben | Chief Scientific Officer | Other(J) | 50K | — | $0 |
| Jul 11, 2022 | Tommasi Ruben | Chief Scientific Officer | Other(J) | 25K | — | $0 |
| Jul 11, 2022 | Tommasi Ruben | Chief Scientific Officer | Other(J) | 6K | — | $0 |
| Jul 11, 2022 | Tommasi Ruben | Chief Scientific Officer | Other(J) | 99K | — | $0 |
| Jul 11, 2022 | Triola Anna Diaz | Chief Commercial Officer | Disposed to issuer(D) | 125K | — | — |
| Jul 11, 2022 | Triola Anna Diaz | Chief Commercial Officer | Other(J) | 100K | — | $0 |
| Jul 11, 2022 | Wagner Kristie Ann | VP, Principal Fin & Acct Off | Disposed to issuer(D) | 81K | — | — |
| Jul 11, 2022 | Wagner Kristie Ann | VP, Principal Fin & Acct Off | Other(J) | 73K | — | $0 |
| Jul 11, 2022 | Innoviva Strategic Opportunities LLC | Insider | Buy(P) | 7.6M | $2.20 | $16.7M |
| Jul 8, 2022 | Innoviva Strategic Opportunities LLC | Insider | Buy(P) | 11.7M | $2.20 | $25.7M |
| Jul 7, 2022 | Altarac David | Chief Medical Officer | Tender(U) | 18K | $2.20 | $39K |
| Jul 7, 2022 | Berger Heather A. | Director | Tender(U) | 22K | $2.20 | $48K |
| Jul 7, 2022 | Hastings David C | Director | Tender(U) | 22K | $2.20 | $48K |
| Jul 7, 2022 | Keiley Elizabeth M | General Counsel | Tender(U) | 18K | $2.20 | $39K |
| Jul 7, 2022 | Mayer Howard | Director | Tender(U) | 22K | $2.20 | $48K |
| Jul 7, 2022 | Meek David D. | Director | Tender(U) | 22K | $2.20 | $48K |
| Jul 7, 2022 | Mueller John Patrick | Chief Development Officer | Tender(U) | 17K | $2.20 | $38K |
| Jul 7, 2022 | Perros Manoussos | President and CEO, Director | Tender(U) | 56K | $2.20 | $123K |
| Jul 7, 2022 | Ronsheim Matthew | Chief of Pharma Sciences & MFG | Tender(U) | 18K | $2.20 | $39K |
| Jul 7, 2022 | Tommasi Ruben | Chief Scientific Officer | Tender(U) | 40K | $2.20 | $87K |
| Feb 24, 2022 | Wagner Kristie Ann | VP, Principal Fin & Acct Off | Grant(A) | 10K | — | $0 |
| Feb 18, 2022 | Innoviva Strategic Opportunities LLC | Director, 10% Owner | Other(J) | 0 | — | — |
| Feb 18, 2022 | Innoviva Strategic Opportunities LLC | Director, 10% Owner | Other(J) | 0 | — | — |
| Jan 18, 2022 | Triola Anna Diaz | Chief Commercial Officer | Grant(A) | 125K | — | $0 |
| Jan 18, 2022 | Altarac David | Chief Medical Officer | Grant(A) | 125K | — | $0 |
| Jan 18, 2022 | Hastings David C | Director | Grant(A) | 28K | — | $0 |
| Jan 18, 2022 | Meek David D. | Director | Grant(A) | 28K | — | $0 |
| Jan 18, 2022 | Keiley Elizabeth M | General Counsel | Grant(A) | 125K | — | $0 |
| Jan 18, 2022 | Behanna Heather | Director | Grant(A) | 28K | — | $0 |
| Jan 18, 2022 | Mayer Howard | Director | Grant(A) | 28K | — | $0 |
| Jan 18, 2022 | Mueller John Patrick | Chief Development Officer | Grant(A) | 125K | — | $0 |
| Jan 18, 2022 | Perros Manoussos | See Remarks | Grant(A) | 125K | — | $0 |
| Jan 18, 2022 | Ronsheim Matthew | See Remarks | Grant(A) | 125K | — | $0 |
| Jan 18, 2022 | Gutch Michael | See Remarks | Grant(A) | 125K | — | $0 |
| Jan 18, 2022 | Tommasi Ruben | Chief Scientific Officer | Grant(A) | 125K | — | $0 |
| Nov 2, 2021 | Tommasi Ruben | Chief Scientific Officer | Tax withholding(F) | 4K | $2.94 | $11K |
| Nov 2, 2021 | Gutch Michael | CFO and Chief Business Officer | Tax withholding(F) | 4K | $2.94 | $11K |
| Nov 2, 2021 | Perros Manoussos | President and CEO, Director | Tax withholding(F) | 12K | $2.94 | $34K |
| Nov 2, 2021 | Mueller John Patrick | Chief Development Officer | Tax withholding(F) | 4K | $2.94 | $11K |
| Nov 2, 2021 | Altarac David | Chief Medical Officer | Tax withholding(F) | 4K | $2.94 | $11K |
| Nov 2, 2021 | Keiley Elizabeth M | General Counsel | Tax withholding(F) | 4K | $2.94 | $11K |
| Nov 2, 2021 | Ronsheim Matthew | Chief, Pharma Sciences & MFG. | Tax withholding(F) | 4K | $2.94 | $11K |
| Oct 19, 2021 | Ronsheim Matthew | See Remarks | Sell(S) | 4K | $3.19 | $12K |
| Oct 19, 2021 | Ronsheim Matthew | See Remarks | Grant(A) | 25K | — | $0 |
| Oct 19, 2021 | Altarac David | Chief Medical Officer | Sell(S) | 4K | $3.19 | $12K |
| Oct 19, 2021 | Altarac David | Chief Medical Officer | Grant(A) | 25K | — | $0 |
| Oct 19, 2021 | Keiley Elizabeth M | General Counsel | Sell(S) | 4K | $3.19 | $12K |
| Oct 19, 2021 | Keiley Elizabeth M | General Counsel | Grant(A) | 25K | — | $0 |
| Oct 19, 2021 | Gutch Michael | See Remarks | Grant(A) | 25K | — | $0 |
| Oct 19, 2021 | Gutch Michael | See Remarks | Sell(S) | 4K | $3.19 | $12K |
| Oct 19, 2021 | Mueller John Patrick | Chief Development Officer | Sell(S) | 4K | $3.19 | $13K |
| Oct 19, 2021 | Mueller John Patrick | Chief Development Officer | Grant(A) | 25K | — | $0 |
| Oct 19, 2021 | Perros Manoussos | See Remarks, Director | Sell(S) | 12K | $3.19 | $38K |
| Oct 19, 2021 | Perros Manoussos | See Remarks, Director | Grant(A) | 80K | — | $0 |
| Jul 19, 2021 | Triola Anna Diaz | Chief Commercial Officer | Grant(A) | 100K | — | $0 |
| Jul 16, 2021 | Keiley Elizabeth M | General Counsel | Grant(A) | 21K | — | — |
| Jul 16, 2021 | Keiley Elizabeth M | General Counsel | Disposed to issuer(D) | 25K | — | — |
| Jul 16, 2021 | Hastings David C | Director | Disposed to issuer(D) | 15K | — | — |
| Jul 16, 2021 | Hastings David C | Director | Grant(A) | 9K | — | — |
| Jul 16, 2021 | Hastings David C | Director | Disposed to issuer(D) | 12K | — | — |
| Jul 16, 2021 | Hastings David C | Director | Grant(A) | 6K | — | — |
| Jul 16, 2021 | Hastings David C | Director | Grant(A) | 12K | — | — |
| Jul 16, 2021 | Hastings David C | Director | Disposed to issuer(D) | 8K | — | — |
| Jul 16, 2021 | Altarac David | Chief Medical Officer | Disposed to issuer(D) | 120K | — | — |
| Jul 16, 2021 | Altarac David | Chief Medical Officer | Grant(A) | 92 | — | — |
| Jul 16, 2021 | Behanna Heather | Director | Grant(A) | 6K | — | — |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Coverage: Form 4 filings indexed 2021-03-29 → 2026-07-11. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).